Clinical trial
Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal…
NCT00443196 · Pierian Biosciences, Industry · Completed
Key facts
| NCT number | NCT00443196 |
|---|---|
| Title | Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas |
| Official title | Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas |
| Lead sponsor | Pierian Biosciences, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Adenocarcinoma, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms |
| Intervention type | Procedure |
| Interventions | MiCK Assay |
| Enrollment | 150 |
| Start date | Mar 1, 2006 |
| Completion | Sep 1, 2010 |
| First posted | Mar 5, 2007 |
| Last update posted | Mar 12, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: